Closely held Cell Technologies is advancing regenerative medicine through proprietary autologous and allogeneic stem cell platforms designed to treat the pain and inflammation associated with osteoarthritis (OA) and...

Closely held PolarityBio is developing investigational regenerative biologics for chronic wound healing, targeting some of the most refractory wounds in medicine. The company’s lead program and first entry into the...

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing...

Closely held Astrocyte Pharmaceuticals is developing a new category of neuroprotective therapies aimed at reducing early brain damage following stroke, concussion, and traumatic brain injury (TBI). By harnessing the...

Closely held First Ascent Biomedical is working to redefine how oncologists select therapies by pairing genomics with a proprietary live-cell testing platform that evaluates how an individual patient’s cancer responds...

For more than two decades, Slone Partners has maintained a dedicated focus on leadership recruitment for life sciences and healthcare organizations. The company’s co-CEO and managing partner, Leslie Loveless, has been...

Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.

Closely held Experity Health is shaping the future of healthcare by embedding AI into urgent care hubs across the U.S. to improve patient access, speed clinical visits, and elevate care quality.

Tyler B. Evans, MD, MS, MPH, is a leading voice in global health equity, infectious disease, and humanitarian medicine. As co-founder, CEO, and chief medical officer of Wellness Equity Alliance (WEA), Dr. Evans has...

Consultancy Cell One Partners is helping innovators translate scientific ambition into viable commercial solutions as the cell and gene therapy industry pushes toward its next era of breakthroughs. Through deep domain...

Closely held Micoy Therapeutics is advancing novel, first-in-class therapeutics to target harmful autoantibodies that induce immunodeficiency by inhibiting immune signaling molecules—type I interferons—which are...

Closely held Likarda is advancing a novel modality for delivering cellular therapies—a proprietary, customizable hydrogel delivery system engineered for controlled release, immune protection, and high cell viability.

Closely held Solu Therapeutics is pairing heterobifunctional small molecules with monoclonal antibodies to develop therapeutic agents that eliminate disease-driving cells in cancer, immunology, and other therapeutic...